The aim of this study is to compare plasma S Protein levels to SARS-CoV-2 viral load inCOVID positive patients.
Non-pharmacological, non-interventional, prospective, monocentric study involving the use
of biological materials.
There will be two cohorts:
- COVID + cohort: 50 patients with positive nasopharyngeal swab and / or BAL.
- Control Cohort: 20 patients with non-SARS-CoV-2 related pneumonia.
The study involves analyzing biological samples collected for normal clinical practice.
In particular:
- blood samples will be used for PROS and Sflt1 assay, haematological, biochemical and
coagulation tests.
- Samples deriving from nasopharyngeal swab or from Broncho-Alveolar Lavage (BAL)
liquid will be used for Real time PCR analysis to evaluate the viral load of SARS
CoV-2.
Procedure: Hematolgy and Chemistry analysis
Samples will be collected at Day 0, Day 5, Day 10 and Day 15
Other Name: Peripheral Blood
Procedure: Real Time PCR
Samples will be collected at Day 0, Day 5, Day 10 and Day 15
Other Name: Nasopharyngeal swab,Bronchoalveolar lavage
Procedure: PROS assay COVID+
Samples will be collected at Day 0, Day 5, Day 10 and Day 15
Other Name: Peripheral Blood
Procedure: Sflt1 assay COVID+
Samples will be collected at Day 0 and Day 10
Other Name: Peripheral Blood
Procedure: PROS assay CONTROL
Samples will be collected at Day 0 (+5)
Other Name: Peripheral Blood
Procedure: Sflt1 assay CONTROL
Samples will be collected at Day 0 (+5)
Other Name: Peripheral Blood
Inclusion Criteria:
Cohort COVID + :
- Subjects aged ≥ 18 years.
- Signing of the informed consent.
- Positivity for SARS-CoV-2 by RealTimePCR from nasopharyngeal swab or bronchial wash.
Cohort Control:
1. Subjects aged ≥ 18 years.
2. Signing of the informed consent.
3. Diagnosis of pneumonia not related to SARS-CoV-2, demonstrated by negative swab.
Exclusion Criteria:
- Patients with a diagnosis of congenital S Protein deficiency.
- Patients who are taking oral anticoagulant therapy (TAO) or new oral anticoagulants
(NAO).
- Chronic liver failure (> 5 points on the Child-Pugh score).
- Female subjects who are pregnant or on estrogen-progestogen replacement therapy.
San Gerardo Hospital
Monza, Lombardia, Italy
Investigator: Luisa Verga, MD
Contact: +39 0392339868
l.verga@asst-monza.it
Daniela Ciulla, M.Sc
+392339883
d.ciulla.hsg@gmail.com
Ivan Civettini, MD
+39 039 2339883
ivan.civettini@hotmail.it
Luisa Verga, MD, Study Director
San Gerardo Hospital